NEW YORK, July 19, 2026, 17:05 EDT — U.S. trading concluded ahead of the weekend.
- Agenus ended Friday’s session at $5.01, trading 0.4% under its Series B warrant price.
- The stock advanced 49.6% over the past week. The biotech index declined 3.0%.
- Initial assessment: a complete issuance may boost the common-equivalent total by 183%.
Agenus NASDAQ:AGEN closed Friday at $5.01, with its main warrant series finishing two cents under the $5.03 exercise price.
The difference is significant. Agenus stands to gain roughly $170 million from the full exercise of Series B warrants. Series A warrants, set at $4.02 each, could provide an additional $85 million.
Both warrant series can be exercised right away, within ownership restrictions. Holders decide when to exercise. Agenus is not assured of receiving the cash even if the share price rises.
The stock rose 49.6% from July 10 to July 17, while the SPDR S&P Biotech ETF (NYSEARCA:XBI) fell 3.0%. Agenus outperformed the benchmark by approximately 52.6 percentage points.
Activity slowed following Monday’s session. The stock ended down 42.4% from its $8.70 high reached that day. On Friday, trading volume fell to 1.72 million shares, a 99% decrease compared to Monday.
The price is now split across three separate tiers of financing:
| Security layer | Purchase or exercise price | Gap to Friday close | Gross proceeds | Potential common equivalents |
|---|---|---|---|---|
| Upfront package | $3.69 | +35.8% | $85 million | 23.0 million |
| Series A warrants | $4.02 | +24.6% | $85 million | 21.1 million |
| Series B warrants | $5.03 | -0.4% | $170 million | 33.8 million |
| Total | — | — | As much as $340 million | 78.0 million |
The gaps reflect comparisons between every reported level and Friday’s regular trading close. All figures are rounded.
An initial dilution estimate highlights the magnitude. The package consists of 78.0 million possible common equivalents, or 183% of the 42.68 million shares Agenus had before the deal.
If fully issued, approximately 120.7 million common equivalents would be outstanding, prior to any further adjustments. Holders from before the deal would account for around 35% of the total.
The compromise is reduced financial runway. Agenus projects that initial funding will support operations until the third quarter of 2027. Exercising all warrants may provide funding up to 2031.
The $85 million gross payment upfront was significant compared to the previous balance sheet. As of March 31, Agenus reported holding $35.0 million. Operating cash consumption in the first quarter totaled approximately $36.0 million.
The latest ownership filing on Friday offered further insight into shareholders. Entities linked to Invus disclosed a beneficial stake limited to 9.99%. The document also verified that the placement was completed on July 15.
The funding will be directed toward ROBBIN, a Phase 3 colon cancer trial involving 850 patients. Agenus anticipates enrolling the first patient in the first quarter of 2027. Interim data on pathologic response are scheduled for release in late 2027.
Chief Medical Officer Steven O’Day stated that MSS colon cancer “has resisted standard checkpoint inhibitors.” Agenus will discontinue its funding for the independent BATTMAN Phase 3 trial. SEC
Phase 1b data reported by the company offers clinical support, though falls short of definitive evidence. Among 123 patients with extensive prior treatment, the median survival was 21.2 months. Three-year survival stood at 33%, and the response rate was 21%.
Friday’s separate update did not provide an immediate readout. Agenus announced it will present three BOT+BAL abstracts at ESMO in Madrid scheduled for October 23-27. One of the neoadjuvant studies focuses on dMMR tumors, differing from the ROBBIN study’s MSS/pMMR cohort.
The published ROBBIN schedule sets its upcoming milestone for 2027. For now, $5.03 stands out as the main near-term indicator in the market. Trading volume will indicate if last week’s momentum continues.
Risks: There is no guarantee of warrant proceeds. Complete exercise would result in significant dilution. ROBBIN remains uninitiated, and initial feedback may not reflect event-free survival. In the Phase 1b group, 15% experienced grade 3 or higher immune-mediated diarrhea or colitis.
